A bold vision for the future of healthcare has been unveiled by the Chan Zuckerberg Initiative (CZI), a philanthropic powerhouse with a mission to eradicate all diseases by the end of the century. With rapid advancements in artificial intelligence (AI) as their catalyst, CZI is taking ambitious steps towards this goal, including the development of a virtual immune system (VIS) and a comprehensive 'Google map' of the human body.
Founded by Priscilla Chan, a pediatrician, and her husband Mark Zuckerberg in 2015, CZI initially aimed to tackle a wide range of societal challenges, from healthcare to education. However, by the early 2020s, the foundation narrowed its focus to scientific pursuits, with a particular emphasis on AI-driven research. Last year, CZI announced a significant increase in research funding and a doubling of investment in AI-based projects, as reported by Science magazine.
The financial commitment from Chan and Zuckerberg is nothing short of extraordinary. They have pledged nearly their entire wealth, which has grown from an initial $45 billion to a staggering $220 billion, to support CZI's mission. This endowment is set to surpass established biomedical foundations like the Novo Nordisk Foundation ($147.5 billion in assets) and the Bill & Melinda Gates Foundation ($77.2 billion as of 2024).
"As I get older, I want to see progress happen faster," Chan explained. "We've reached a point where we can accelerate scientific discovery at an unprecedented pace."
To reinforce its AI focus, CZI appointed Alex Rives, a computer scientist from the Broad Institute of MIT and Harvard University, as its new scientific director. Rives, who has developed large language models for biology and previously worked as an AI researcher at Facebook, will lead CZI's efforts in this field.
One of CZI's flagship projects is the development of a VIS, a large-scale AI initiative aimed at accelerating the discovery of new therapies. This project, recently presented as a preprint, will receive a significant boost in funding, with plans to expand computing capacity at the Biohub by tenfold over the next three years.
Researchers at the Biohub in New York are at the forefront of this effort, genetically modifying immune cells to study their functional transitions and migration patterns within the body. Led by biophysicist Andrea Califano, president of immune cell reprogramming and head of the New York Biohub, the team is altering the genetic programs of immune cells to observe the resulting changes in behavior, activation, and tissue localization.
By the end of this year, researchers plan to modify approximately 100 million individual cells and record the molecular and functional changes systematically. "Our goal is to create mechanisms that allow us to study the immune system as a unified system," Califano explained.
The Biohub in Chicago is also contributing to this initiative by studying inflammation in organoids, laboratory-grown tissue clusters. Researchers are developing sensors to sample these organoids hourly, tracking protein and metabolic changes associated with conditions like psoriasis and inflammatory bowel diseases.
While immunologist Jeffrey Bluestone, head of Sonoma Biotherapeutics, expressed skepticism about the VIS being the key to curing all diseases, he acknowledged its potential to revolutionize immunology. "It won't cure everything," he said, "but it could be transformative by answering critical questions about influenza virus infection and improving vaccine development."
CZI is also supporting the International Human Cell Atlas Initiative, a project described as a 'Google map' of the human body. This initiative aims to map all human cell types across the lifespan, providing a comprehensive understanding of cellular interactions.
A consortium led by Stanford biophysicist Steve Quake at the San Francisco Biohub has created a separate atlas, cataloging over one million cells from 28 human organs and mapping their interactions.
Since 2019, CZI has funded a network of patient-led organizations focused on rare diseases. In July 2025, CZI announced its first investment in a treatment-related project, allocating $20 million over three years to the University of California, San Francisco, and Berkeley, to test personalized CRISPR treatments in eight children with severe genetic immune disorders. This builds upon the successful gene therapy reported earlier this year in the case of 'Baby KJ,' an infant with a rare metabolic disease.
Additionally, CZI is supporting the development of a virtual cell, a digital twin of a human cell, where cellular processes can be simulated in real-time and pathological mechanisms studied. Chan estimates that this goal could be achieved within the next five years.
"Leading CZI towards these ambitious objectives feels urgent," Chan said. "People need hope, and I want to believe that the impossible is indeed possible."
This story, originally published in Medscape's German edition, highlights the exciting and controversial potential of AI-driven research in healthcare.
